KDM4B: A Nail for Every Hammer?

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2019 Feb 15

PMID 30759871

Citations 27

Authors

Cailin Wilson

Adam J Krieg

Affiliations

Soon will be listed here.

Abstract

Epigenetic changes are well-established contributors to cancer progression and normal developmental processes. The reversible modification of histones plays a central role in regulating the nuclear processes of gene transcription, DNA replication, and DNA repair. The KDM4 family of Jumonj domain histone demethylases specifically target di- and tri-methylated lysine 9 on histone H3 (H3K9me3), removing a modification central to defining heterochromatin and gene repression. KDM4 enzymes are generally over-expressed in cancers, making them compelling targets for study and therapeutic inhibition. One of these family members, KDM4B, is especially interesting due to its regulation by multiple cellular stimuli, including DNA damage, steroid hormones, and hypoxia. In this review, we discuss what is known about the regulation of KDM4B in response to the cellular environment, and how this context-dependent expression may be translated into specific biological consequences in cancer and reproductive biology.

Citing Articles

Targeting N-Methyl-lysine Histone Demethylase KDM4 in Cancer: Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery.

Cursaro I, Milioni L, Eslami K, Sirous H, Carullo G, Gemma S ChemMedChem. 2024; 20(4):e202400682.

PMID: 39498961 PMC: 11831885. DOI: 10.1002/cmdc.202400682.

Triple Combinations of Histone Lysine Demethylase Inhibitors with PARP1 Inhibitor-Olaparib and Cisplatin Lead to Enhanced Cytotoxic Effects in Head and Neck Cancer Cells.

Dorna D, Kleszcz R, Paluszczak J Biomedicines. 2024; 12(6).

PMID: 38927566 PMC: 11201379. DOI: 10.3390/biomedicines12061359.

KDM4B mutations in human cancers.

Bush W, Bosart K, Bouley R, Petreaca R Mutat Res. 2024; 829:111866.

PMID: 38878505 PMC: 11585459. DOI: 10.1016/j.mrfmmm.2024.111866.

circBRAF promotes the progression of triple-negative breast cancer through modulating methylation by recruiting KDM4B to histone H3K9me3 and IGF2BP3 to mRNA.

Lan J, Wang L, Cao J, Wan Y, Zhou Y Am J Cancer Res. 2024; 14(5):2020-2036.

PMID: 38859856 PMC: 11162659. DOI: 10.62347/OOLG5765.

Genotype-phenotype correlation study of structural abnormalities in a fetal brain caused by a novel KDM4B variant.

Zhao X, Li X, Yu M, Jia J, Tian R, Zhu F Mol Biol Rep. 2024; 51(1):188.

PMID: 38270710 DOI: 10.1007/s11033-023-09092-y.

References

Black J, Manning A, Van Rechem C, Kim J, Ladd B, Cho J . KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell. 2013; 154(3):541-55. PMC: 3832053. DOI: 10.1016/j.cell.2013.06.051. View

Tsurumi A, Dutta P, Dutta P, Shang R, Yan S, Sheng R . Drosophila Kdm4 demethylases in histone H3 lysine 9 demethylation and ecdysteroid signaling. Sci Rep. 2013; 3:2894. PMC: 3792421. DOI: 10.1038/srep02894. View

Castellini L, Moon E, Razorenova O, Krieg A, von Eyben R, Giaccia A . KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. Nucleic Acids Res. 2017; 45(7):3674-3692. PMC: 5397198. DOI: 10.1093/nar/gkw1281. View

Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Pedersen M, Kooistra S, Radzisheuskaya A, Laugesen A, Johansen J, Hayward D . Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development. EMBO J. 2016; 35(14):1550-64. PMC: 4899663. DOI: 10.15252/embj.201593317. View

Tsukada Y, Fang J, Erdjument-Bromage H, Warren M, Borchers C, Tempst P . Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2005; 439(7078):811-6. DOI: 10.1038/nature04433. View

Yang J, Jubb A, Pike L, Buffa F, Turley H, Baban D . The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010; 70(16):6456-66. PMC: 4261152. DOI: 10.1158/0008-5472.CAN-10-0413. View

Black J, Atabakhsh E, Kim J, Biette K, Van Rechem C, Ladd B . Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes Dev. 2015; 29(10):1018-31. PMC: 4441050. DOI: 10.1101/gad.259796.115. View

10.

Chan D, Giaccia A . Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007; 26(2):333-9. DOI: 10.1007/s10555-007-9063-1. View

11.

Filiu-Braga L, Serejo T, Lucena-Araujo A, Neves F, de Carvalho J, Rego E . Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia. Med Oncol. 2018; 36(1):3. DOI: 10.1007/s12032-018-1226-0. View

12.

Yang J, Harris A, Davidoff A . Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer. Int J Mol Sci. 2018; 19(1). PMC: 5796188. DOI: 10.3390/ijms19010240. View

13.

Young L, McDonald D, Hendzel M . Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation. J Biol Chem. 2013; 288(29):21376-21388. PMC: 3774405. DOI: 10.1074/jbc.M113.491514. View

14.

Yang J, AlTahan A, Hu D, Wang Y, Cheng P, Morton C . The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. J Natl Cancer Inst. 2015; 107(6):djv080. PMC: 4555638. DOI: 10.1093/jnci/djv080. View

15.

Vakoc C, Mandat S, Olenchock B, Blobel G . Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin. Mol Cell. 2005; 19(3):381-91. DOI: 10.1016/j.molcel.2005.06.011. View

16.

Wang Z, Zang C, Rosenfeld J, Schones D, Barski A, Cuddapah S . Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008; 40(7):897-903. PMC: 2769248. DOI: 10.1038/ng.154. View

17.

Peng J, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A . Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell. 2010; 139(7):1290-302. PMC: 2911953. DOI: 10.1016/j.cell.2009.12.002. View

18.

Black J, Van Rechem C, Whetstine J . Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012; 48(4):491-507. PMC: 3861058. DOI: 10.1016/j.molcel.2012.11.006. View

19.

Whetstine J, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z . Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006; 125(3):467-81. DOI: 10.1016/j.cell.2006.03.028. View

20.

Ramachandran S, Ient J, Gottgens E, Krieg A, Hammond E . Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia. Genes (Basel). 2015; 6(4):935-56. PMC: 4690023. DOI: 10.3390/genes6040935. View